Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications

被引:39
作者
Kettering, Melanie [1 ]
Zorn, Heike [1 ]
Bremer-Streck, Sibylle [2 ]
Oehring, Hartmut [3 ]
Zeisberger, Matthias [4 ]
Bergemann, Christian [5 ]
Hergt, Rudolf [4 ]
Halbhuber, Karl-Juergen [3 ]
Kaiser, Werner A. [1 ]
Hilger, Ingrid [1 ]
机构
[1] Univ Hosp Jena, Inst Diagnost & Intervent Radiol, D-07747 Jena, Germany
[2] Univ Hosp Jena, Inst Clin Chem & Lab Med, D-07747 Jena, Germany
[3] Univ Hosp Jena, Inst Anat 2, D-07743 Jena, Germany
[4] Inst Photon Technol, D-07745 Jena, Germany
[5] Chemicell GmbH, D-12103 Berlin, Germany
关键词
FUNCTIONALIZED MAGNETIC NANOPARTICLES; IN-VIVO TRACKING; CANCER-CHEMOTHERAPY; TUMOR-CELLS; MITOMYCIN-C; HYPERTHERMIA; PARTICLES; VITRO; DNA; THERMOABLATION;
D O I
10.1088/0031-9155/54/17/003
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
The aim of this study was to characterize the behaviour of cisplatin adsorbed magnetic nanoparticles (cis-MNPs) for minimal invasive cancer treatments in preliminary in vitro investigations. Cisplatin was adsorbed to magnetic nanoparticles (MNPs) by simple incubation. For stability determinations, cis-MNPs were incubated in dH(2)O, phosphate-buffered saline (PBS) and fetal calf serum (FCS) at 4-121 degrees C up to 20 weeks. Hydrodynamic diameters were measured using laser diffraction. The extent of cisplatin linkage was determined by atomic absorption spectrometry. The magnetite core size was assessed by vibrating sample magnetometry and transmission electron microscopy. The specific loss power (SLP) was measured in an alternating magnetic field. Our results showed that a maximum of 10.3 +/- 1.6 (dH(2)O), 10 +/- 1.6 (PBS) and 13.4 +/- 2.2 (FCS) mg cisplatin g(-1) Fe could be adsorbed to MNPs. With hyperthermal (42 degrees C) or thermal ablative (60 degrees C) temperatures, used for therapeutic approaches, cisplatin did not desorb from cis-MNPs in dH(2)O during incubation times of 180 or 30 min, respectively. In PBS and FCS, cisplatin amounts adsorbed to MNPs decreased rapidly to approximately 50% and 25% at these temperatures. This cisplatin release will be necessary for successful chemotherapeutic activity and should increase the therapeutic effect of magnetic heating treatment in medicinal applications. The hydrodynamic diameters of MNPs or cis-MNPs were around 70 nm and magnetization data showed superparamagnetic behaviour. The obtained mean core diameter was around 12 nm. The SLP of the sample was calculated to be 75.5 +/- 1.6 W g(-1). In conclusion, cis-MNPs exhibit advantageous features for a facilitated desorption of cisplatin in biological media and the heating potential is adequate for hyperthermic treatments. Therefore, even though further detailed investigations are still necessary, tentative use in local tumour therapies aiming at a specific chemotherapeutic release in combination with magnetic heating seems to be feasible in the long term.
引用
收藏
页码:5109 / 5121
页数:13
相关论文
共 42 条
[1]   Magnetic drug targeting - Biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment [J].
Alexiou, C ;
Jurgons, R ;
Schmid, RJ ;
Bergemann, C ;
Henke, J ;
Erhardt, W ;
Huenges, E ;
Parak, F .
JOURNAL OF DRUG TARGETING, 2003, 11 (03) :139-149
[2]   Targeting cancer cells: magnetic nanoparticles as drug carriers [J].
Alexiou, Christoph ;
Schmid, Roswitha J. ;
Jurgons, Roland ;
Kremer, Marcus ;
Wanner, Gerhard ;
Bergemann, Christian ;
Huenges, Ernst ;
Nawroth, Thomas ;
Arnold, Wolfgang ;
Parak, Fritz G. .
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2006, 35 (05) :446-450
[3]   In vitro analysis of cisplatin functionalized magnetic nanoparticles in combined cancer chemotherapy and electromagnetic hyperthermia [J].
Babincova, Melania ;
Altanerova, Veronika ;
Altaner, Cestmir ;
Bergemann, Christian ;
Babinec, Peter .
IEEE TRANSACTIONS ON NANOBIOSCIENCE, 2008, 7 (01) :15-19
[4]  
BARLOGIE B, 1980, CANCER RES, V40, P1165
[5]   Magnetic ion-exchange nano- and microparticles for medical, biochemical and molecular biological applications [J].
Bergemann, C ;
Müller-Schulte, D ;
Oster, J ;
à Brassard, L ;
Lübbe, AS .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 1999, 194 (1-3) :45-52
[6]   Functionalisation of magnetic nanoparticles for applications in biomedicine [J].
Berry, CC ;
Curtis, ASG .
JOURNAL OF PHYSICS D-APPLIED PHYSICS, 2003, 36 (13) :R198-R206
[7]  
Bohren C. F., 1998, ABSORPTION SCATTERIN, DOI 10.1002/9783527618156
[8]   Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells [J].
Bulte, JWM ;
Douglas, T ;
Witwer, B ;
Zhang, SC ;
Strable, E ;
Lewis, BK ;
Zywicke, H ;
Miller, B ;
van Gelderen, P ;
Moskowitz, BM ;
Duncan, ID ;
Frank, JA .
NATURE BIOTECHNOLOGY, 2001, 19 (12) :1141-1147
[9]   MEASUREMENTS OF PARTICLE-SIZE DISTRIBUTION PARAMETERS IN FERROFLUIDS [J].
CHANTRELL, RW ;
POPPLEWELL, J ;
CHARLES, SW .
IEEE TRANSACTIONS ON MAGNETICS, 1978, 14 (05) :975-977
[10]   Recent advances in iron oxide nanocrystal technology for medical imaging [J].
Corot, Claire ;
Robert, Philippe ;
Idee, Jean-Marc ;
Port, Marc .
ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (14) :1471-1504